Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a  randomized phase 2 trial (LEOPARD-2)

ConclusionGiven the limitations of this trial, radiochemotherapy plus cetuximab was feasible. There was a  trend towards improved PFS and MFS. Larger studies are required to better define the role of cetuximab for unresectable esophageal cancer.

Source: Strahlentherapie und Onkologie - June 11, 2020 Category: Cancer & Oncology Source Type: research